Form 4: InMed Director Granted Stock Options

InMed Pharmaceuticals Inc. Director John Steven Bathery was granted 1,750 employee stock options with an exercise price of $1.29, vesting in one year.

Summary

• John Steven Bathery, a Director of InMed Pharmaceuticals Inc. (INM), acquired 1,750 employee stock options.
• The options have an exercise price of $1.29 per share.
• The grant date for these options was December 19, 2025.
• The options will vest 100% on December 18, 2026, or immediately prior to the next Annual General Meeting, whichever occurs sooner.
• The expiration date for these options is December 18, 2030.
• Following this transaction, Mr. Bathery beneficially owns 5,250 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of stock options to a director is a standard practice that aligns management interests with shareholders, which is generally viewed favorably. However, it is a routine compensation event and not indicative of significant operational or financial news.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified directors.

Future Outlook

The vesting schedule for the granted options, set for December 18, 2026, or earlier upon the next Annual General Meeting, indicates a future alignment of the director's incentives with the company's long-term performance and shareholder value creation.

Industry Context

The grant of stock options to a director is a common form of executive and board compensation across various industries, particularly in biotechnology and pharmaceuticals, aiming to align leadership interests with long-term company growth and shareholder returns.

Comparison to Industry Standards

• Equity-based compensation, such as stock options, is a widely accepted practice for compensating non-executive directors in publicly traded companies, including those in the pharmaceutical sector like InMed Pharmaceuticals Inc.
• The vesting schedule, typically over one to three years, is standard for ensuring continued commitment and performance from directors.
• The specific number of options granted (1,750) and the exercise price ($1.29) would need to be compared against peer companies of similar market capitalization and stage of development to assess if it is within industry norms for director compensation packages.

Corporate Governance

Related Party Transactions

• The grant of employee stock options to Director John Steven Bathery constitutes a related party transaction, as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance. However, future exercise could lead to minor dilution.
• Employees: This specific filing pertains to director compensation and does not directly impact the broader employee base, though it reflects the company's approach to equity incentives for key personnel.

Next Steps

• The options will vest 100% on December 18, 2026, or immediately prior to the next Annual General Meeting, whichever is sooner, at which point the director will be able to exercise them.

Key Dates

Keywords

InMed Pharmaceuticals, INM, stock options, director compensation, beneficial ownership, equity grant, insider transaction